Advanced Solid Tumor Clinical Trials in Los Angeles, California

20 studies are recruiting for advanced solid tumor in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

   This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California

   Locations

   37 in total

   Run by

   BeOne Medicines

   See if you can join NCT06233942 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California Norris Comprehensive, Los Angeles, California

   Locations

   28 in total

   Run by

   BeOne Medicines

   See if you can join NCT05981703 on ClinicalTrials.gov

4. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

6. A Study of IDP-001 in Advanced or Metastatic Solid Tumors

   This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   InduPro, Inc.

   See if you can join NCT07602842 on ClinicalTrials.gov

7. SW-682 in Advanced Solid Tumors

   This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, California

   Locations

   8 in total

   Run by

   SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06251310 on ClinicalTrials.gov

8. Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   # 1019, UCLA, Westwood Cancer Center, Los Angeles, California

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

9. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

10. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars Sinai, Los Angeles, California

    Locations

    47 in total

    Run by

    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

11. A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California

    Locations

    52 in total

    Run by

    BeOne Medicines

    See if you can join NCT06625593 on ClinicalTrials.gov

12. A Study of PYX-201 in Advanced Solid Tumors

    The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ronald Reagan UCLA Medical Center, Los Angeles, California

    Locations

    29 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT05720117 on ClinicalTrials.gov

13. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

14. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California - Los Angeles, Los Angeles, California

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

15. First in Human Study of TORL-1-23 in Participants With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA - JCCC Clinical Research Unit, Los Angeles, California

    Locations

    14 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT05103683 on ClinicalTrials.gov

16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC - Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

17. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    14 in total

    Run by

    Volastra Therapeutics, Inc.

    See if you can join NCT05902988 on ClinicalTrials.gov

18. A Study of LM-24C5 For Advanced Solid Tumors

    To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    6 in total

    Run by

    LaNova Medicines Limited

    See if you can join NCT06187402 on ClinicalTrials.gov

19. A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA - JCCC Clinical Research Unit, Los Angeles, California

    Locations

    10 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT06005740 on ClinicalTrials.gov

20. This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

    This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC, Los Angeles, California

    Locations

    8 in total

    Run by

    ABL Bio, Inc.

    See if you can join NCT04762641 on ClinicalTrials.gov